Filing Flows

Filing Flows › Companies › Guardant Health › Report card

Guardant Health earnings report card

Every report on file against what analysts and the company itself expected, and what the stock did

Beat rate3 of 5 reports beat the EPS estimate

Guardant Health (GH) beat the analysts' EPS estimate in 3 of its last 5 reports (60%), by +3.8% on average. On report days the stock moved 10.5% in either direction on median (largest 32.8%), rising 60% of the time; after a beat it rose 67% of the time.

Beat rate60% of 5
Average surprise+3.8%
Median move on the day±10.5%
Rose on the day60%

Report by report

QuarterReportedEPS est.EPS reportedSurpriseRevenue reportedStock, the dayvs market
Q3 2026Nov 5, 2026−$0.31−$0.29+7.8%$361M-10.5%-6.4%
Q2 2026Jul 30, 2026−$0.39−$0.42-7.8%$335M+12.4%+10.0%
Q1 2026May 7, 2026−$0.47−$0.45+5.0%$302M+3.7%+3.2%
Q4 2025Feb 19, 2026−$0.47−$0.50-6.5%$281M-4.0%-4.5%
Q3 2025Oct 29, 2025−$0.49−$0.39+20.3%$265M+32.8%+33.9%

Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.

Charts

Guardant Health: EPS reported against the estimateGuardant Health: EPS reported against the estimateEstimateReported−$0.49−$0.39Q3 2025−$0.47−$0.50Q4 2025−$0.47−$0.45Q1 2026−$0.39−$0.42Q2 2026−$0.31−$0.29Q3 2026
Latest (Q3 2026): Estimate −$0.31, Reported −$0.29.
GH: the stock's move on each report dayGH: the stock's move on each report dayQ3 2026-10.5%Q2 2026+12.4%Q1 2026+3.7%Q4 2025-4.0%Q3 2025+32.8%
Close to close around the report, from the daily price history.

The earnings-day move

Over 5 reports the stock moved 10.5% on median on the day (close to close), the largest move 32.8%.

After a beat the stock rose 67% of the time (3 beats); after a miss it fell 50% of the time (2 misses).

The next report: what to expect → Guardant Health: every quarter →

Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.